IMF calls for 'urgent' action by India amid slowdown

Washington, Feb 21: Days ahead of his India visit, US President Donald Trump on Thursday said the two countries could make a "tremendous" trade deal.

"We're going to India, and we may make a tremendous deal there," Trump said in his commencement address at the Hope for Prisoners Graduation Ceremony in Las Vegas.

Trump, accompanied by First Lady Melania Trump, is scheduled to travel to Ahmedabad, Agra and New Delhi on February 24 and 25.

Ahead of the visit, there have been talks about India and the United States agreeing on a trade package as a precursor to a major trade deal.

During his commencement address, Trump indicated that the talks on this might slowdown if he did not get a good deal.

"Maybe we'll slow down. We'll do it after the election. I think that could happen too. So, we'll see what happens," he said.

"But we're only making deals if they're good deals because we're putting America first. Whether people like it or not, we're putting America first," Trump said.

Bilateral India-US trade in goods and services is about three per cent of the US' world trade.

In a recent report, the Congressional Research Service (CRS) said the trading relationship is more consequential for India -- in 2018 the United States was its second largest goods export market (16.0 per cent share) after the European Union (EU, 17.8 per cent), and third largest goods import supplier (6.3 per cent) after China (14.6 per cent) and the EU 28 (10.2 per cent).

"The Trump Administration takes issue with the US trade deficit with India, and has criticised India for a range of 'unfair' trading practices," the CRS said.

"Indian Prime Minister Modi's first term fell short of many observers' expectations, as India did not move forward with anticipated market opening reforms, and instead increased tariffs and trade restrictions," it said.

"Modi's strong electoral mandate may embolden the Indian government to press ahead with its reform agenda with greater vigour. Slowing economic growth in India raises concerns about its business environment," CRS said.

As per a fact sheet issued by the Council on Foreign Relations (CFR), trade in goods and services between the two countries from 1999 to 2018 surged from $16 billion to $142 billion.

India is now the United States' eighth-largest trading partner in goods and services and is among the world's largest economies.

India's trade with the United States now resembles, in terms of volume, the US' trade with South Korea ($167 billion in 2018) or France ($129 billion), said Alyssa Ayres from CFR.

"The United States for two years now has set out in stone pretty clearly the things that they wanted to see to try to get an agreement, and it's basically then on India's doorstep on whether they want to take those steps," Rick Rossow, Wadhwani Chair in US-India Policy Studies at the Center for Strategic and International Studies think-tank told reporters during a conference call.

"The list of US asks has been pretty static all throughout. Not to say that any of these things are easy for India to do, but the United States to my knowledge didn't change the goalposts just because we now consider India to be a middle-income country. The things that we wanted to see happen to get this trade agreement have been pretty static all throughout, no matter how difficult they are," he said in response to a question.

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

Wuhan, Jun 9: China on Tuesday dismissed as "incredibly ridiculous" a Harvard study, which pointed to a surge in traffic outside Wuhan hospitals from August 2019 suggesting that the coronavirus hit the area far earlier than reported.

A whitepaper on coronavirus released by China on Sunday said the virus was first noticed on December 17 and Chinese virologists confirmed human-to-human transmission on January 19, prompting authorities to impose lockdown of Wuhan from January 23.

US President Donald Trump and leaders of several countries have accused China of not being transparent in reporting the deadly disease, leading to huge human casualties and economic crisis across the world.

The new study by Harvard researchers says satellite images show an increase in traffic outside five hospitals in Wuhan from late August to December.

The traffic spike coincided with a rise in online searches for information on symptoms like "cough" and "diarrhoea".

China said the study was "ridiculous" and based on "superficial" information, BBC reported.

It is believed that the virus first appeared in China some time in November. Authorities reported a cluster of pneumonia cases with an unknown cause to the World Health Organization (WHO) on December 31.

"Clearly, there was some level of social disruption taking place well before what was previously identified as the start of the novel coronavirus pandemic," Dr John Brownstein, who led the research, told ABC news.

The study has not been peer-reviewed.

The researchers examined commercial satellite data from outside five Wuhan hospitals, comparing data from late summer and autumn 2018 to the same time period in 2019.

In one case, researchers counted 171 cars parked at one of Wuhan''s largest hospitals, Tianyou Hospital, in October 2018.

Satellite data from the same time in 2019 showed 285 vehicles in the same place, an increase of 67 per cent.

A surge in online searches for words associated with the symptoms of coronavirus on the Chinese search engine Baidu seemed to emerge at the same time.

"This is all about a growing body of information pointing to something taking place in Wuhan at the time," Dr Brownstein said.

"Many studies are still needed to fully uncover what took place and for people to really learn about how these disease outbreaks unfold and emerge in populations. So this is just another point of evidence," he said.

Asked for her reaction at the media briefing, Chinese Foreign Ministry spokeswoman Hua Chunying dismissed the findings as "incredibly ridiculous".

"I think it is ridiculous, incredibly ridiculous, to come up with this conclusion based on superficial observations such as traffic volume," she said.

"(I have) Not seen the research you mentioned. If the conclusion is drawn based on traffic volumes (and) other superficial observations, it won’t be a sound conclusion," she said and referred to the allegations about the COVID-19 originating from the Wuhan Institute of Virology (WIV) by Trump.

"That allegation was proved to be wrong," she said.

When pointed out that China says it respects science based inquiry and Harvard is one of the top universities in the world, Hua said, "on the origin of virus there are lot of conspiracy theories against China”.

"That is very unfair. At the moment, the pressing task is to enhance coordination to contain the spread of the virus. Someday, I am sure the truth will be out. China deserves a fair and objective evaluation," she said and referred to the whitepaper released by the Chinese government detailing evolution of coronavirus in Wuhan and how Beijing handled the situation.

Recently, the World Health Assembly (WHA), the decision-making body of Geneva-based World Health Organization (WHO), passed a resolution to probe the origin of the virus. China also backed the resolution.

As of Monday, the overall confirmed cases on the mainland had reached 83,043, including 58 patients who were still being treated, with no one in severe condition, China’s National Health Commission, (NHC) said.

Altogether 78,351 people had been discharged after recovery and 4,634 people had died of the disease, it said.